Marex Group’s Filana Therapeutics FLNA Stock Holding History

Marex Group’s Portfolio FLNA Stock Details FLNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$18.4K	Buy	15,500 +5,000	+48%	+$7.12K	﹤0.01%	1102
2026 Q1	$17.7K	Buy	+10,500	New	+$21.6K	﹤0.01%	987

Other funds holding FLNA

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

GMT Capital Atlanta, Georgia $1.92B AUM 70.51% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Squarepoint New York $90.5B AUM 33.95% 1-Year Est. Return

Marex Group's FLNA Position: Q2 2026 in Review

Marex Group increased its Filana Therapeutics (FLNA) stake by 48% in Q2 2026, buying an estimated $7.12K and bringing the position to 15,500 shares worth $18.4K. The position accounts for ﹤0.01% of the portfolio, ranked #1102.

Marex Group first reported a position in FLNA in Q1 2026 and has held it in 2 quarters since. 85 funds tracked by Wall St. Rank hold FLNA as of Q2 2026.

Marex Group held 15,500 shares of Filana Therapeutics worth $18.4K as of Q2 2026.
Marex Group bought 5,000 Filana Therapeutics shares in Q2 2026, an estimated $7.12K.
Filana Therapeutics made up ﹤0.01% of Marex Group's portfolio in Q2 2026, its #1102 holding.
Marex Group first reported a position in Filana Therapeutics in Q1 2026 and has held it in 2 quarters since.
85 funds tracked by Wall St. Rank held Filana Therapeutics as of Q2 2026.

Based on Marex Group's 13F filing for Q2 2026, filed 14 Aug 2026.